Utilizing TH9 cells as a novel therapeutic strategy for malignancies

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Lu, Yong ^a   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ccl20; DCs; Melanoma; TCLs; Th9 cell

Indexed keywords

CHEMOKINE RECEPTOR CCR6; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL KILLING; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; HELPER CELL; IMMUNOREGULATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TH9 CELL; THERAPY EFFECT; TUMOR IMMUNITY; UPREGULATION;

EID: 84886943372     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23084     Document Type: Article

References (10)

1. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci U S A 1988; 85:6934-8; PMID:3137580; http://dx.doi.org/10.1073/pnas.85.18.6934.
2. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9:1341-6; PMID:18931678; http://dx.doi.org/10.1038/ni.1659.
3. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010; 10:683-7; PMID:20847745; http://dx.doi.org/10.1038/nri2848.
4. Soroosh P, Doherty TA. Th9 and allergic disease.Immunology 2009; 127:450-8; PMID:19604299; http://dx.doi.org/10.1111/j.1365-2567.2009.03114.x.
5. Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie AN, et al.IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression.J Immunol 2011; 186:83-91; PMID:21115728; http://dx.doi.org/10.4049/jimmunol.1001183.
6. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, et al.Th9 cells promote antitumor immune responses in vivo.J Clin Invest 2012; 122:4160-71; PMID:23064366; http://dx.doi.org/10.1172/JCI65459.
7. Li Q, Guo Z, Xu X, Xia S, Cao X. Pulmonary stromal cells induce the generation of regulatory DC attenuating T-cell-mediated lung inflammation. Eur J Immunol 2008; 38:2751-61; PMID:18825748; http://dx.doi.org/10.1002/eji.200838542.
8. Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.J Immunol 2009; 182:6207-16; PMID:19414774; http://dx.doi.org/10.4049/jimmunol.0803926.
9. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al.Differential antigen processing by dendritic cell subsets in vivo.Science 2007; 315:107-11; PMID:17204652; http://dx.doi.org/10.1126/science.1136080.
10. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.J Clin Invest 2004; 113:774-83; PMID:14991076.